CHMP recommends Ryzneuta (efbemalenograstim alpha) to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy.-Evive Biotecnology
On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ryzneuta, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy
The applicant for this medicinal product is Evive Biotechnology Ireland Limited.Ryzneuta will be available as a 20 mg solution for injection. The active substance of Ryzneuta is efbemalenograstim alfa, an immunostimulant/colony stimulating factor (ATC code: L03AA18) that belongs to the class of haematopoietic growth factors (granulocyte colony stimulating factor; G CSF) which increase the production and differentiation of mature and functionally active neutrophils from bone marrow precursor cells.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins